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Abstract
This review considers primary mitochondrial diseases affecting the respiratory chain. As diseases due to mitochondrial
DNA defects defy traditional anatomical classifications, we have not limited our discussion to neuromuscular disorders, but
have extended it to include mitochondrial encephalomyopathies. Primary mitochondrial diseases can be due to mutations in
either the nuclear or the mitochondrial genome. Nuclear mutations can affect (i) genes encoding enzymatic or structural
mitochondrial proteins; (ii) translocases; (iii) mitochondrial protein importation; and (iv) intergenomic signaling. We review
briefly recent molecular data and outstanding questions regarding these mendelian disorders, with special emphasis on
cytochrome c oxidase deficiency and coenzyme Q10 deficiency. Mitochondrial DNA mutations fall into three main
categories : (i) sporadic rearrangements (deletions/duplications) ; (ii) maternally inherited rearrangements (duplications); and
(iii) maternally inherited point mutations. We summarize the most common clinical presentations and discuss pathogenic
mechanisms, which remain largely elusive. Uncertainties about pathogenesis extend to the process of cell death, although
excitotoxicity in neurons and apoptosis in muscle seem to have important roles. ß 1998 Elsevier Science B.V. All rights
reserved.
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1. Introduction
This fourth section of the issue on Mitochondria in
Cell Death deals with the primary or secondary in-
volvement of mitochondria in speci¢c human dis-
eases. We consider our task that of discussing disor-
ders due to primary mitochondrial dysfunction and
a¡ecting the neuromuscular system. In taking up
such a task, we are immediately faced with two prob-
lems: (i) the number of bona ¢de primary mitochon-
drial diseases has ballooned in the past 10 years,
especially after the discovery of pathogenic muta-
tions in mitochondrial DNA (mtDNA) [1,2]; (ii)
the ubiquitous distribution of mitochondria makes
classical anatomical classi¢cations of diseases unten-
able for mtDNA-related disorders. Thus, ‘neuromus-
cular disorders’ in the traditional sense are rarely
seen in patients with mtDNA mutations, who tend
to have multisystemic disorders, often a¡ecting pre-
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dominantly brain, nerve, and muscle only because
these tissues are highly dependent on oxidative me-
tabolism and are, therefore, especially vulnerable to
defects of mitochondrial function. As a way of cir-
cumventing these problems, we will not even attempt
to review the increasingly vast spectrum of mitochon-
drial diseases, which are described in recent text-
books [3^6], and we will consider the term ‘neuro-
muscular disorders’ as non-restrictive and essentially
equivalent to ‘mitochondrial cytopathies’.
Mitochondria are under the control of two ge-
nomes, one of which (the nuclear genome) not only
encodes the vast majority of mitochondrial proteins,
but also controls mitochondrial protein transport
and several vital mtDNA functions, whereas the oth-
er (the mitochondrial genome) is the relic of a ‘for-
eign’ DNA, which re£ects the symbiotic relationship
between primordial bacteria and eukaryotic cells.
Thus, the genetic classi¢cation of mitochondrial dis-
eases is rather complex (Table 1).
2. Disorders due to defects of nuclear DNA
Disorders due to defects of nuclear DNA (nDNA)
are all transmitted by mendelian inheritance, but
come in several varieties.
2.1. Defects of genes encoding enzymatic or structural
mitochondrial proteins
There are a multitude of inherited errors of metab-
olism due to mitochondrial enzyme defects, and these
can involve any of the several metabolic pathways
within mitochondria, including pyruvate and fatty
acid oxidation, amino acid synthesis, citric acid cycle,
the electron-transport chain, and oxidative phos-
phorylation. In this review, we will con¢ne our at-
tention to defects of the electron-transport chain and
oxidative phosphorylation, that is, of the respiratory
chain, the only area of metabolism where the two
genomes cooperate (Fig. 1).
Purely based on the vast numerical preponderance
of nDNA- versus mtDNA-encoded proteins in the
respiratory chain (71:13, Fig. 1), it would be ex-
pected that most disorders due to respiratory chain
enzyme defects would be mendelian. In fact, present
evidence would suggest that the opposite is true,
although this impression may simply be due to the
enormous amount of work done on mtDNA during
the past ten years. In sharp contrast to the over 50
pathogenic mutations described in mtDNA, only one
mutation has been identi¢ed in a nuclear gene, that
encoding the £avoprotein subunit of complex II [7].
This situation will certainly change in the years to
come, because there is good, if indirect, evidence that
many neuromuscular or generalized syndromes are
due to mutations of nDNA-encoded subunits of the
respiratory chain. The evidence is based on pedigree
analysis (suggesting mendelian, usually autosomal re-
cessive, inheritance), and biochemical studies (show-
ing severe de¢ciency of a single respiratory chain
complex).
Typical examples of this situation are three distinct
pediatric syndromes associated with cytochrome oxi-
dase (COX, complex IV) de¢ciency. One of them is
Leigh syndrome (LS), a devastating encephalopathy
with characteristically symmetric lesions of the basal
ganglia and the brainstem: of the numerous recog-
nized etiologies of LS, COX de¢ciency appears to be
the most common [8]. Although the nuclear origin of
this disorder has been established by elegant somatic
cell genetic studies [9,10], no molecular defect has
been identi¢ed in any of the 10 nuclear subunits of
COX [11,12]. Complementation analysis using heter-
okaryons derived from direct fusion of ¢broblasts
from di¡erent patients showed three complementa-
tion groups in one study [13], but only one group
in another [14]. Thus, genetic heterogeneity is likely,
though one mutation may predominate. Because
nDNA-encoded COX components were normal, the
a¡ected gene (or genes) probably controls COX as-
sembly or stability: numerous genes have these func-
tions in yeast and several human analogs have been
described and are good candidates for LS [15,16].
The other two syndromes associated with COX
de¢ciency are tissue-speci¢c and cause severe gener-
alized myopathy in infancy. One of them is invaria-
bly fatal within a year (‘fatal infantile myopathy’
[17]), whereas the other is spontaneously reversible
(‘benign infantile myopathy’ [18]), implying the in-
volvement of a COX subunit that is not only
muscle-speci¢c but also developmentally regulated.
Molecular analyses of the genes encoding the two
tissue-speci¢c nuclear subunits of COX (COX VIa
and COX VIIa) have been unrevealing [11], and the
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molecular bases of these two diseases remain ob-
scure.
We will discuss brie£y another mendelian disease
due to a respiratory chain defect, primary coenzyme
Q10 (CoQ10) de¢ciency, for two main reasons: (i)
we may be seeing just the tip of the iceberg of a
disorder more common and clinically heterogeneous
than we thought; and (ii) patients with CoQ10 de¢-
ciency seem to respond dramatically to replacement
therapy, making a correct diagnosis extremely impor-
tant from a practical point of view.
The ¢rst patients with muscle CoQ10 de¢ciency
were two sisters, who, after a normal early develop-
ment, developed exercise intolerance and proximal
limb weakness [19]. Brain involvement became man-
ifest at age 5, with learning disability in both girls,
seizures in one, and cerebellar ataxia in the other. In
addition, both sisters had recurrent myoglobinuria
after seizures or febrile illnesses. Muscle biopsy
showed mitochondrial proliferation with ‘ragged-red
¢bers’ (RRF) in the Gomori trichrome histochemical
stain, and excessive accumulation of lipid droplets.
The same syndrome, characterized by the triad of
mitochondrial myopathy with RRF, recurrent myo-
globinuria, and brain involvement with seizures, has
recently been ‘rediscovered’ in three patients, a 35-
year-old woman [20], and two young brothers [21].
All ¢ve patients had extremely low levels of CoQ10
in skeletal muscle, but normal concentrations in se-
rum and in cultured ¢broblasts, and all ¢ve bene¢ted
greatly from CoQ10 administration. At the latest
meeting of the American Society of Human Genetics,
an apparently more generalized defect of CoQ10 was
described in two infant siblings with ‘encephalomy-
opathy and renal failure’, who also improved mark-
edly with CoQ10 administration [22]. Although no
primary biochemical defect has yet been identi¢ed,
the complexity of CoQ10 biosynthesis may readily
explain how defects at di¡erent sites may cause dif-
Table 1
Genetic classi¢cation of the mitochondrial diseases
Nuclear DNA defects (mendelian inheritance)
A. Defects of genes encoding enzymatic or structural
proteins
B. Defects of mitochondrial translocases
C. Defects of mitochondrial protein importation
D. Defects of intergenomic signaling
Mitochondrial DNA defects
A. Sporadic large-scale rearrangements
(duplications/deletions)
B. Maternally inherited point mutations
Fig. 1. The mitochondrial respiratory chain. Nuclear DNA-encoded subunits are shaded, mtDNA-encoded subunits are hatched. Pro-
tons (H) are pumped from the matrix to the intermembranous space through complexes I, III, and IV. They £ow back into the ma-
trix though complex V (ATP synthetase) with the concomitant production of ATP. Coenzyme Q10 (CoQ) and cytochrome c (Cyt c)
are nucleus-encoded electron transfer proteins.
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ferent clinical syndromes. It also suggests that still
other clinical presentations may be related to
CoQ10 de¢ciency and their discovery could lead to
e¡ective therapy.
2.2. Disorders due to defects of translocases
Translocases are essential for the ‘tra⁄cking’ of
metabolites across the inner mitochondrial mem-
brane (another reminder of the ‘foreign’ origin of
mitochondria). Although many translocases have
been studied in detail [23], few have been involved
in human mitochondrial disorders. A notable excep-
tion is the carnitine-acylcarnitine translocase: a de-
fect of this transporter protein was documented bio-
chemically in 1992 [24], and a molecular defect has
been recently identi¢ed in one patient (F. Palmieri,
personal communication). More important as a
cause of respiratory chain dysfunction is a de¢ciency
of the adenine nucleotide translocator (ANT). This
has been described in one child with mitochondrial
myopathy, and has been attributed to a speci¢c de-
fect of the muscle/heart subunit ANT1 [25]. The lack
of cardiac symptoms in that child at age 8 is a little
surprising, because a ‘knockout’ mouse de¢cient in
ANT1 showed not only mitochondrial myopathy but
also hypertrophic cardiomyopathy with mitochon-
drial proliferation [26]. These ANT1 null mutant
mice are the ¢rst animal models of mitochondrial
myopathy/cardiopathy and will be invaluable tools
for the study of pathogenetic mechanisms and for
the exploration of therapeutic approaches.
A transporter in the outer mitochondrial mem-
brane, the voltage-dependent anion channel
(VDAC), also known as porin, was markedly de-
creased in the muscle biopsy from a child with dys-
morphic features, hypotonia, developmental delay,
seizures, and hydrocephalus [27]. Although the rates
of pyruvate oxidation and ATP production were de-
creased in muscle mitochondria, there was no lactic
acidosis, and muscle histochemistry and the activities
of individual mitochondrial enzymes were normal,
making the diagnosis of this entity problematic.
2.3. Disorders due to defects of mitochondrial protein
importation
Except for the 13 polypeptides encoded by
mtDNA, all other mitochondrial proteins have to
be imported from the cytoplasm and directed to
the appropriate submitochondrial compartment (out-
er membrane, intermembranous space, inner mem-
brane, matrix). This complex process requires an
equally complex machinery, which has been largely
dissected and understood in the past decade [28].
Addressing the proteins to the mitochondria is ac-
complished through targeting signals, highly basic
‘leader peptides’ located at the N-terminus of most
imported polypeptides. Docking to and getting
across the mitochondrial membranes requires import
receptors and channels, located at sites of outer and
inner membrane apposition. It also requires unfold-
ing and refolding of the proteins by heat shock pro-
teins or ‘chaperonins’. Once the proteins are inside
the mitochondrion, the leader peptides are removed
by intramitochondrial peptidases.
Considering the complexity of this multistep proc-
ess, it may appear surprising that relatively few hu-
man disorders have been attributed to defects of pro-
tein importation. This point has not escaped the
attention of Wayne Fenton, who, in a thoughtful
editorial [29], suggested that genetic errors involving
importation steps shared by multiple proteins would
presumably be lethal, whereas defects involving indi-
vidual proteins (e.g. mutations in leader peptides)
would manifest as single enzyme defects. This opin-
ion is bolstered by two experimental observations:
(i) most diseases due to faulty mitochondrial protein
importation are, in fact, mutations in leader peptides
resulting in single enzyme defects, such as methylma-
lonic acidemia [30] or E1K pyruvate dehydrogenase
complex de¢ciency [31] ; and (ii) defective synthesis of
heat shock protein 60 (hsp60) has been described in
one infant with multiple mitochondrial enzyme de-
fects, who survived only 2 days, a virtually lethal
condition [32].
2.4. Disorders due to defects of intergenomic signaling
This is a particularly interesting group of disorders
because the primary genetic lesion is in the nDNA
(and, therefore, inheritance is mendelian), but the
consequence of the nuclear mutation is an abnormal-
ity of mtDNA, as if the normal ‘dialogue’ between
the two genomes had been disrupted. This is due to
the fact that, in the course of evolution, the symbi-
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otic protobacteria have lost much of their autonomy
and have become increasingly dependent on the host
cell’s genome, which encodes numerous factors con-
trolling mtDNA replication, transcription and trans-
lation.
Defects of mtDNA replication result in mtDNA
depletion, which can be more or less severe and, pe-
culiarly, is tissue-speci¢c [33]. The severe form of
mtDNA depletion (with less than 10% residual
mtDNA) typically causes a congenital myopathy or
a congenital hepatopathy (this is one of the few iso-
lated liver diseases due to mitochondrial dysfunc-
tion); not surprisingly, both conditions are fatal
within the ¢rst year of life. Less severe mtDNA de-
pletion (with 20^40% residual mtDNA) is usually
associated with later-onset myopathy, starting at
about 1 year of age and causing respiratory failure
and death in childhood. However, we have come to
realize that the clinical spectrum of what is presum-
ably primary, autosomal recessive mtDNA depletion
is wider and may include signs of central or periph-
eral nervous system involvement [34]. Serum creatine
kinase (CK) is usually markedly elevated, which is an
unusual ¢nding in other mitochondrial myopathies,
and represents a useful diagnostic clue [35]. There are
also examples of secondary mtDNA depletion, such
as the iatrogenic mitochondrial myopathy observed
in patients with AIDS treated with zidovudine, a
nucleoside analog that probably interferes at the
same time with viral and with mtDNA replication
[36,37]. In other diseases, such as inclusion body my-
ositis with multiple mtDNA deletions [38], there is
focal mtDNA depletion a¡ecting individual muscle
¢bers (T. Vu and E. Bonilla, personal communica-
tion).
The etiology and pathogenesis of primary mtDNA
depletion remain unknown. Complementation stud-
ies have con¢rmed data from pedigree analysis sug-
gesting that this is a nDNA problem [39,40], but the
defective gene (or genes) remain elusive. Cultured
¢broblasts expressing mtDNA depletion also had
low levels of mitochondrial transcription factor A
(mtTFA), a transcriptional activator involved in the
formation of a short RNA primer required for the
initiation of mtDNA replication [41,42], but this may
be a consequence rather than a cause of mtDNA
depletion. Primary myoblasts as well as myoblast
clone lines from a patient with muscle mtDNA de-
pletion showed either normal or variably decreased
levels of mtDNA, but in all cells there was a pro-
gressive decline of mtDNA concentration with in-
creasing passage numbers [40]. This suggested that
the still elusive defective nuclear product may be a
tissue-speci¢c and developmentally regulated trans-
acting factor whose mutation causes an arrest of
mtDNA replication.
The second group of disorders due to defects of
intergenomic signaling is characterized by the pres-
ence in skeletal muscle of multiple mtDNA deletions
[43]. The clinical hallmark in these patients is paral-
ysis of eye muscles, or progressive external ophthal-
moplegia (PEO), which can be isolated or associated
with a variety of other symptoms, such as exercise
intolerance, limb weakness, cardiomyopathy, cata-
racts, hearing loss, and psychosis. Inheritance can
be autosomal dominant or recessive. In patients
with autosomal dominant PEO (AD-PEO), symp-
toms tend to be con¢ned to the musculature, whereas
patients with autosomal recessive PEO (AR-PEO)
generally have multisystem involvement [44]. A spe-
cial form of multisystemic AR-PEO is the mitochon-
drial neurogastrointestinal encephalomyopathy
(MNGIE) syndrome, in which gastrointestinal dys-
function and peripheral neuropathy are prominent
[45]. In a comparative study of muscle from patients
with AD-PEO or AR-PEO, we have found that the
number of RRF (an expression of mitochondrial
proliferation) and of cytochrome oxidase-negative
(COX-negative) ¢bers (an expression of mitochon-
drial dysfunction) was greater in AD-PEO, as was
the abundance of the multiple mtDNA rearrange-
ments [44].
As the di¡erent inheritance patterns indicate, these
disorders are genetically heterogeneous. Linkage
analysis has identi¢ed two loci in some (but not
all) families with AD-PEO, one on chromosome 10
[46], the other on chromosome 3 [47], and, predict-
ably, a di¡erent locus (on chromosome 22) in four
ethnically distinct families with MNGIE (M. Hirano,
personal communication). However, the mutant
genes and the encoded factors remain unknown.
3. Disorders due to defects of mtDNA
Although mtDNA has been known since the early
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1960s, it came into the clinical limelight only in 1988,
when the ¢rst pathogenic mutations were discovered
[1,2]. The extraordinary progress in our awareness of
mtDNA-related diseases is illustrated by the morbid-
ity map of mtDNA (Fig. 2). The variety of mtDNA-
related diseases requires that clinicians become famil-
iar with mitochondrial genetics, which di¡ers from
mendelian genetics in several ways.
Polyplasmy. In contrast with nDNA genes, which
are represented by a paternal and a maternal allele,
cells contain multiple mitochondria and each mi-
tochondrion contains multiple genomes, such that
each cell contains hundreds or thousands of copies
of mtDNA. At cell division, mitochondria and
mtDNAs distribute randomly in daughter cells.
Thus, mitochondrial genetics is, in a very real sense,
population genetics.
Heteroplasmy. In normal tissues, all mtDNA mol-
ecules are identical (homoplasmy). A mutation in
mtDNA may a¡ect all genomes (another example
of homoplasmy), or it may a¡ect only some of the
genomes, such that the tissue will harbor two popu-
lations of mtDNA, wild-type mtDNA and mutant
mtDNA, a situation called heteroplasmy. Usually,
neutral polymorphisms of mtDNA are homoplasmic,
whereas most (but not all) pathogenic mutations are
heteroplasmic.
Threshold e¡ect. It is rather intuitive that the clin-
ical expression of a pathogenic mtDNA mutation
will be largely determined by the relative proportion
of wild-type and mutant genomes in di¡erent tissues
and that a minimum critical number of mutant
mtDNAs will be needed for each tissue to become
dysfunctional, a concept aptly labeled ‘threshold ef-
fect’. As the dependence of di¡erent tissues on oxi-
dative metabolism varies widely, so does their vulner-
ability to oxidative stress, and their mutational
threshold.
Mitotic segregation. At cell division, the propor-
tion of mutant mtDNAs in daughter cells may
vary, thus explaining why in mtDNA-related disor-
ders both genotype and clinical phenotype may ac-
tually change in time. This phenomenon is exempli-
¢ed by some children with Pearson’s syndrome (PS),
a severe sideroblastic anemia of infancy, who survive
this usually fatal hemopoietic disorder only to devel-
op later in life a severe encephalomyopathy (Kearns-
Sayre syndrome, KSS ^ see below). As the molecular
basis of both conditions is a single deletion in
mtDNA, it is likely that the proportion of deleted
mtDNAs decreases in successive generations of rap-
idly replicating blood cell, while it increases with time
in postmitotic tissues such as brain and muscle.
Maternal inheritance. At fertilization, all mtDNA
derives from the oocyte, an interesting phenomenon
apparently due to a general process of active elimi-
nation of sperm mtDNA, not only by the ovum but
also by somatic cells [48]. Therefore, the mode of
transmission of mtDNA (and of mtDNA point mu-
tations) is by vertical, maternal inheritance: a mother
carrying a mtDNA point mutation will pass it to all
her children, of both sexes, but only her daughters
will transmit the mutation to their progeny. Maternal
transmission may not be immediately apparent at the
clinical level: due to heteroplasmy and the threshold
e¡ect, di¡erent individuals in the matrilinear lineage
of the same family may be severely a¡ected, oligo-
symptomatic, or totally una¡ected.
A review of the remarkable clinical spectrum of
mtDNA-related diseases is beyond the scope of the
present article (for review, see [49]), but we will con-
sider brie£y the biological characteristics and clinical
consequences of the two major types of mtDNA mu-
tation: rearrangements and point mutations.
3.1. Sporadic rearrangements of mtDNA
Sporadic rearrangements of mtDNA consist of sin-
gle deletions or duplications. More often than not,
these rearrangements are present together in the
same patient: when this happens, the deletion and
the duplication are related structurally, and it seems
likely that duplications are recombination intermedi-
ates, which then resolve into deletions [50]. The im-
portant point is that any one patient has a single type
of rearranged molecule, probably resulting from clo-
nal expansion of a spontaneous deletion and/or du-
plication event that occurred in oogenesis or early in
embryogenesis. This concept has recently been bol-
stered by the observation that oocytes from normal
women contain very low levels of rearranged
mtDNA molecules [51]. Of the approximately
100 000 mtDNAs present in a fertilized oocyte, only
about 1000 will repopulate the fetus, which creates a
narrow bottleneck. Once in a while a rearranged
mtDNA molecule will slip through this bottleneck
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and segregate into one or more of the fetus’ tissues,
resulting in an apparently sporadic condition.
There are three main clinical entities associated
with sporadic mtDNA deletions/duplications: (i)
Kearns-Sayre syndrome (KSS) is a multisystem dis-
order de¢ned by the triad of early onset (before age
20), PEO, and pigmentary retinopathy, plus at least
one additional feature among the following: heart
block, cerebellar syndrome, or CSF protein higher
than 100 mg/dl. The course is relentlessly downhill,
even after placement of a cardiac pacemaker, and
death usually occurs before the third decade. Muscle
biopsy shows RRF, which are COX-negative by his-
tochemistry. (ii) Pearson syndrome (PS) manifests in
infancy as a severe hematopoietic disorder, with side-
roblastic anemia and exocrine pancreas dysfunction
[52]. As mentioned above, the few children that out-
live the blood disease go on to develop KSS later in
life [53,54]. (iii) Sporadic PEO with RRF is a rela-
tively benign condition characterized by ptosis, oph-
thalmoplegia, and proximal limb weakness, usually
with a rather indolent course compatible with a nor-
mal lifespan.
There are two main pathogenetic questions. The
¢rst is, Why are partial deletions of the mtDNA
circle deleterious? Solid evidence indicates that loss
of tRNA genes, at least one of which is always en-
compassed by even the smallest sporadic deletions,
impairs mitochondrial protein synthesis. The second
question is, How can the same molecular defect
cause such disparate clinical presentations? The
most likely explanation is that the few rearranged
mtDNA molecules that slip through the oocyte/em-
bryo bottleneck segregate in a highly skewed fashion
among germ layers at the blastocyst stage (when
mtDNA replication resumes and germ layer di¡er-
entiation begins). Thus, in KSS and PS there is prob-
ably segregation into all three layers, but with a pref-
erence for the hematopoietic lineage in PS, whereas
in PEO deleted mtDNAs segregate almost exclusively
to the myogenic lineage.
A special case is represented by small-scale dele-
tions, whose mode of inheritance is uncertain. An
apparently sporadic case of mitochondrial myopathy
with recurrent myoglobinuria was associated with a
heteroplasmic deletion of only 15 bp in the COX III
gene, which removed ¢ve in-frame amino acids in the
polypeptide [55].
3.2. Maternally inherited rearrangements of mtDNA
While there is not yet any evidence that single
mtDNA deletions are inherited, there are a few dis-
orders in which duplications/deletions are maternally
transmitted. These conditions are usually associated
with diabetes as the main, or even the sole clinical
feature [56^58], but we observed a patient with pure
myopathy [59].
In patients with deletions/duplications, what is the
pathogenic role of the duplicated mtDNA molecules?
In theory, duplications could alter mitochondrial
function by subverting the normal relative ratios of
tRNAs, or by generating abnormal proteins from the
chimeric fusion genes straddling the duplication
breakpoints [50]. In practice, however, it appears
that duplications have little, if any, role in pathogen-
esis, except in that they may be the source of dele-
tions. In a patient with myopathy, who harbored
about 40% duplicated but only about 1% deleted
mtDNA molecules in muscle, mitochondrial prolifer-
ation and COX negativity correlated with the pres-
ence of deletions, not duplications [59].
3.3. Point mutations of mtDNA
As mentioned above, over 50 pathogenic point
mutations have been documented [6,50], in associa-
tion with a bewildering spectrum of clinical presen-
tations. Here, we will only provide ‘bullet’ descrip-
tions of the ¢ve most common clinical syndromes.
(i) Myoclonus epilepsy with ragged-red ¢bers
(MERRF) is characterized by myoclonus, general-
ized seizures, cerebellar ataxia, and myopathy. Onset
can be in childhood or in adult life and the course
can be slowly progressive or rapidly downhill. As
implied by the acronym, muscle biopsy shows
RRF, which are typically COX-negative. Most
MERRF patients harbor a mutation (A8344G) in
the tRNALys gene [60].
(ii) Mitochondrial encephalomyopathy, lactic acido-
sis, and stroke-like episodes (MELAS) is typically
associated with a point mutation at nt 3243
(A3243G) in the tRNALeuUUR gene [61]. The clini-
cal hallmark of this syndrome are the stroke-like
episodes with hemiparesis or hemianopia, almost in-
variably occurring before age 40, and often in child-
hood. Common additional features include focal or
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generalized seizures, recurrent migraine-like head-
ache and vomiting, and dementia. The course is
one of gradual deterioration. Muscle biopsy shows
RRF, which are typically COX-positive, a distinc-
tive histochemical feature from both KSS and
MERRF.
(iii) Neuropathy, ataxia, retinitis pigmentosa
(NARP) is a multisystem disorder of young adult
Fig. 2. ‘Morbidity map’ of human mitochondrial DNA (mtDNA), updated to January 1, 1998. The map of the 16 569 bp mtDNA
shows di¡erently shaded areas representing the structural genes for the seven subunits of complex I (NADH-CoQ oxidoreductase,
ND), the three subunits of cytochrome oxidase (COX), cytochrome b (Cyt b), and the two subunits of ATP synthetase (ATPase 6
and 8), the 12S and 16S ribosomal RNAs (rRNA), and the 22 transfer RNAs (tRNA) identi¢ed by one-letter codes for the corre-
sponding amino acids (modi¢ed from [6]).
Fig. 3. Evidence of apoptosis in ragged-red ¢bers (RRF) from a patient with progressive external ophthalmoplegia (PEO). (a) Succi-
nate dehydrogenase (SDH) stain shows two hyperintense RRF (white circles) ; (b) TUNEL shows labeling of nuclei (small arrows) in
the two RRF (white circles); (c) the cytochrome oxidase (COX) stain shows that the RRF are COX-negative (white circles). U82.5.
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life comprising, in various combinations, sensory
neuropathy, ataxia, seizures, dementia, and retinitis
pigmentosa [62]. Muscle biopsy shows no RRF. The
main molecular defect is a point mutation (T8993G)
in the structural gene that encodes ATPase 6.
(iv) Maternally inherited Leigh syndrome (MILS)
is a more severe clinical expression of the ‘NARP
mutation,’ manifesting in infancy with developmental
delay, hypotonia, seizures, pyramidal signs, ataxia,
retinitis pigmentosa, and with the neuroradiological
and neuropathological features of LS [63]. The di¡er-
ence in age at onset and severity between NARP and
MILS appears to be due to the di¡erent abundance
of the mutation: about 70% of total mtDNA in
NARP, close to homoplasmy in MILS [64]. A milder
Leigh-like syndrome is caused by a di¡erent base
substitution (T8993C) at the very same nucleotide
[65].
(v) Leber hereditary optic neuropathy (LHON)
causes loss of vision in young adults, predominantly
males. Muscle biopsy is virtually normal, although
biochemical analysis may show complex I de¢ciency.
Over a dozen point mutations have been associated
with LHON, but only three of them are considered
‘primary’, that is, capable of causing symptoms in
the absence of additional ‘synergistic’ mutations.
All three primary mutations are in genes encoding
subunits of complex I (G3460A in ND1; G11778A
in ND4; T14484C in ND6 [66]).
The pathogenetic mechanisms of mtDNA point
mutations are even more puzzling than those of
mtDNA rearrangements. On the one hand, there is
good evidence from experiments employing cytoplas-
mic hybrids, or ‘cybrids’ (a culture system in which
mitochondria from patients are transferred to im-
mortalized human cells that are devoid of their
own mtDNA ^ b0 cells [67]) that the point mutations
in tRNA genes associated with MERRF and
MELAS impair mitochondrial protein synthesis. On
the other hand, and in view of their similar biochem-
ical consequences, it is not clear why mutations in
di¡erent tRNAs should cause di¡erent clinical pic-
tures, such as MERRF and MELAS. In the case of
MELAS, the pathogenesis of the stroke-like events
remains obscure: speci¢cally, we do not know
whether these are ‘metabolic strokes’ or the
result of small vessel angiopathy, a view supported
by the abnormal accumulation of mitochondria in
the walls of small arteries in muscle and brain
[68,69].
It is rather intuitive that the consequences of mu-
tations in speci¢c protein-encoding genes may be dif-
ferent from those of mutations in tRNA genes, which
impair overall mitochondrial protein synthesis, but
here, too, conundrums abound. For example, why
should a generalized defect of complex I, the pre-
sumed biochemical hallmark of LHON, a¡ect so se-
lectively the optic nerve? The fact that RRF are typ-
ically seen in muscle from patients with tRNA gene
mutations (and also from patients with mtDNA re-
arrangements or mtDNA depletion) but not in
muscle from patients with mutations in structural
genes has long suggested that impairment of mito-
chondrial protein synthesis triggers mitochondrial
proliferation in muscle. However, the actual signal
remains elusive. In addition, we are seeing increasing
numbers of exceptions to this general rule, as illus-
trated by three patients with typical MELAS, RRF
in their muscle biopsies, but mutations in structural
genes [70^72].
Although the special rules of mitochondrial genet-
ics can explain many clinical and biochemical pecu-
liarities of mitochondrial diseases, the fundamental
reasons for tissue and symptom speci¢city remain
elusive. In a recent review [50], we have considered
various hypothetical explanations, including di¡eren-
tial tissue vulnerability to mutations in di¡erent sites
of the tRNA cloverleaf; an ‘indirect’ e¡ect of
mtDNA mutations through involvement of the im-
mune system (possibly in LHON); or a selective
damage to tissues involved in transport functions,
such as the pancreatic islet cells, the retinal pigment
epithelium, or the distal renal tubular cells, possibly
mediated through a ‘compartmentalized’ defect of
ATP.
As far as the brain is concerned, we know from
routine neuropathology that there are di¡erent pat-
terns of brain involvement in di¡erent mtDNA-re-
lated syndromes [73]. For example, the white matter
is predominantly involved in KSS, with ‘spongy en-
cephalopathy’; multifocal encephalomalacia, usually
involving the occipital cerebral cortex, characterizes
the stroke-like lesions of MELAS; neuronal degen-
eration and astrocytosis are prominent in the dentate
nucleus and the inferior olivary nucleus in MERRF.
An intriguing scenario that could explain both the
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neuropathological diversity and the di¡erences in
clinical presentations postulates that di¡erent muta-
tions have distinct spatial distribution in the brain.
Some support for this hypothesis has come from im-
munohistochemical studies using antibodies against
mtDNA-encoded and nDNA-encoded subunits of
respiratory chain complexes [74], but developing a
‘mutation map’ of the brain will require in situ hy-
bridization techniques; while these have been utilized
to localize large-scale deletions in muscle [75], accu-
rate in situ hybridization for point mutations is
a formidable and still unmet challenge. Even if
we will be able to document mutation-speci¢c brain
territories, this will still beg the question of which
factors are responsible for the selective higher
abundance of di¡erent mutations in speci¢c brain
areas.
4. Cell death in mitochondrial encephalomyopathies
It is intuitive to think that in mitochondrial en-
cephalomyopathies cells die because of lack of ad-
equate energy provision. Studies of both patients’
tissues and cybrid cell lines have shown good corre-
lation between abundance of a mtDNA mutation
and pathology or cell dysfunction, with threshold
values usually hovering around 90^95% for point
mutations and 80^85% for rearrangements, con¢rm-
ing an old observation of Sho¡ner et al. [60] that
small amounts of wild-type genomes are su⁄cient
to protect tissues from defects of oxidative phospho-
rylation.
The correlation between abundance of the muta-
tion and ATP production, however, is more perplex-
ing. For example, ¢broblasts harboring virtually ho-
moplasmic levels of the NARP/MILS mutation
(T8993G) show only about a 50% decrease in ATP
synthesis [76]. If data in vitro re£ect what happens in
neurons in vivo, we would have to come to the sur-
prising conclusion that chronic depletion of the
steady-state levels of a cell’s ATP by one half is suf-
¢cient to kill that cell, and the patient. It is, of
course, possible that in the patient’s brain the degree
of ATP reduction is closer to 90% than to 50%. It is
also possible that ATP synthesis in neurons is limited
by substrate availability: we found that ATP synthe-
sis in cultured ¢broblasts was 50% of normal with
succinate as a substrate, but 90% of normal with
malate as a substrate [76].
In neurons, even a partial energy crisis could cause
cell death through the mechanism of excitotoxicity
[77]. Inability to maintain adequate ATP levels
would lead to partial neuronal depolarization, thus
abolishing the voltage-dependent Mg2 block of the
N-methyl-D-aspartate (NMDA) receptor, and caus-
ing persistent receptor activation by ambient gluta-
mate. Abnormal NMDA receptor activation would
then cause excessive calcium in£ux, which would fur-
ther impair mitochondrial function, increase free rad-
ical generation, and activate nitric oxide synthase.
In muscle, there is indirect evidence that cell dam-
age is chronic and subacute in most mitochondrial
encephalomyopathies: as mentioned above, serum
CK levels, a good index of muscle necrosis, are either
normal or only mildly elevated in all conditions ex-
cept mtDNA depletion. Accordingly, no ultrastruc-
tural damage of the plasma membrane is seen in
RRF, except in biopsies from children with mtDNA
depletion [78].
When muscle cells die, they seem to do so via
apoptosis. This is suggested by immunohistochemical
studies in muscle biopsies from patients with
mtDNA deletions, in which RRF expressed ubiquitin
[79], bcl-2, and Bax, proteins that have been linked
to the apoptotic process [80,81]. In addition, using
the terminal deoxynucleotidyl transferase-mediated
dUTP nick end-labeling (TUNEL) methodology
[82], we have been able to document DNA breaks
in nuclei of RRF (Fig. 3).
Primary mitochondrial disorders are not only fas-
cinating from a clinical point of view, but they have
also o¡ered basic scientists invaluable models for a
better understanding of mitochondrial biogenesis and
bioenergetics. We still have many questions regard-
ing pathogenetic mechanisms, including the processes
leading to the terminal event, cell death, but there is
no question that important clues will be provided by
careful studies of these patients, in whom a variety of
mitochondrial dysfunctions are unquestionably the
primary pathogenic triggers of cell death.
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